Company Introduces Its Latest Innovation In Regenerative Treatment Solutions
Salt Lake City, UT — (May 16, 2016) – Predictive Technology Group, Inc. (OTC PINK: PRED), announces that its wholly-owned subsidiary, Predictive Biotech, Inc. has finalized the development process of a new allograft stem cell product derived from umbilical cord blood (UCB).
The use of UCB stem cells has gained popularity in medical science owing to their ability to transform into any type of human cells. UCB refers to the blood and tissue that remains in the attached umbilical cord and placenta after childbirth. UCB derived stem cells are considered unique in their applicability in treating many different diseases and disorders including fusion, wound healing, pain management, genetic and hematopoietic disorders.
Eric Olson, President and CEO of Predictive Biotech, Inc., said, “We are very excited to announce that we have completed the development of our latest biologic product. The ‘CoreCell’ liquid suspension product which is rich in proteins and cells is a strong addition to our current regenerative product portfolio.”
Mr. Olson continues, “The new ‘CoreCell’ product added to our allograft portfolio brings together a full selection of regenerative solutions in three core products, UBC, amniotic liquid suspension products, and amniotic membrane. This group of allograft products gives our clinicians the flexibility to choose the optimum solution depending on the patient indication and personal preference.
Predictive Biotech is currently negotiating with several large orthobiologic distributors to launch the product domestically and internationally. The Company is also considering private label opportunities and plans to eventually distribute the product through its own direct sales organization.
About Predictive Technology Group, Inc.
Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of severe and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and acquires proprietary technologies that open windows into the origin of human illness and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to prevent and treat diseases effectively, www.predictivetechnologygroup.com and www.predrx.com.
About Predictive Biotech, Inc.
Predictive Biotech, Inc. is a cellular and regenerative medicine company, focused on the development, processing and distribution of innovative allograft tissues, stem cells and biomaterials for the treatment of serious and debilitating diseases. The company develops and acquires technologies that incorporate the use of genome sequencing with proprietary tissue/stem cell recovery to ensure the highest quality treatment options for its surgeon customers and their patients.
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.